ClinicalTrials.gg
Active, not recruitingNCT07949123INSPiREUpdated Nov 19, 2026

INSPiRE - INtercostal Single Port Robot Evaluation

An interventional study of Anatomic lung resection procedure in NSCLC Stage II and NSCLC Stage I, sponsored by Regina Elena Cancer Institute. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Regina Elena Cancer Institute · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Dec 2025, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy — 156 open to participants now, 287 under way, 105 of them phase 3. Carcinoma, Non-Small-Cell Lung · Italy.

Planned enrollment
590th of 640
30 · median 251
Started
2025
with 55 others
No phase
25 of 716
12 open now
Primary completion
2026-10
later than 96 of 286 live
Registered
716th of 716
by date

Among the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, this one is the 590th largest by planned enrollment of the 640 interventional ones that give a count, is one of 56 that started in 2025, is one of 25 with no phase, reaches primary completion later than 96 of the 286 other live ones, and was the 716th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

156 of the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy are open now. Recruiting first, the newest first:

151 more — sign in →

All 156 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, or all of them as a file.
02

Study summary

To investigate potential major intraoperative and postoperative complications associated with the use of the DaVinci SP® robotic system-via either an intercostal or subcostal approach-during anatomical lung resections in thoracic surgery.

Major complications include: intraoperative conversion to a different surgical technique (thoracoscopy, multi-port robotic surgery) or a different access method (thoracotomy, placement of additional trocars); the need for unplanned intraoperative maneuvers not included in the standard surgical procedure; and the development of bronchopleural fistulas within 10 days.

A single-center, randomized, two-arm (1:1) pilot experimental study on a surgical procedure, investigating the use of two different approaches with the Da Vinci SP® robotic system for anatomical lung resections in thoracic surgery.

03

Conditions studied

  • NSCLC Stage II
  • NSCLC Stage I

Keywords

  • lung cancer
  • DaVinci SP® Robot
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Fit for minimally invasive thoracic surgery under general anesthesia;
  • Clinical stage I-II NSCLC;
  • Eligible for anatomical lung resection (segmentectomy, lobectomy, bilobectomy);
  • No prior surgical interventions or invasive procedures on the affected hemithorax;
  • Presence of a primary or secondary pulmonary neoplasm with an indication for surgery;
  • for study participation and data processing, provided in writing-personally and/or via a witness-before any study-specific procedure is performed.

Exclusion criteria

Exclusion Criteria:

  • Previous interventions on the affected hemithorax (including thoracotomies, VATS, drainage procedures, or invasive )
  • Prior thoracic radiotherapy on the same side
  • Planned need for conversion to thoracotomy
  • Inability to complete 30-day follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Arm A subcostal access

    Lateral subcostal incision between the costal margin and the upper abdomen

    Procedure: Anatomic lung resection procedure

  • Experimental
    Arm B intercostal access

    intercostal access in the 5th-6th anterolateral intercostal space

    Procedure: Anatomic lung resection procedure

Interventions

  • ProcedureAnatomic lung resection procedure

    Anatomic lung resection procedure for NSCLC, to be performed using the Da Vinci SP® robot.

06

What researchers measure

Primary outcomes

  1. Total percentage of major complications

    Evaluate the percentage of total major complications (intraoperative and postoperative). Complications are defined as: intraoperative conversion to a different technique (thoracoscopy, multi-port robotic surgery) or a different surgical approach (thoracotomy, placement of additional trocars); the need for unplanned intraoperative maneuvers not included in the standard procedure; or the occurrence of bronchopleural fistulas.

    Time frame: Within 10 days

Secondary outcomes

  1. Docking time

    Docking time is defined as the time interval, expressed in minutes, between the skin incision and the first maneuver performed at the console.

    Time frame: 100 minutes

  2. Volume of pleural drainage

    collection and monitoring of pleural volume, expressed in milliliters.

    Time frame: 30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Oct 2026, 10 months.

Of 344 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 98. This study's 10 months is below that.

Counting every sponsor, half of 360 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 19, 2026
StartActual
Dec 17, 2025
Primary completionActual
Oct 26, 2026
CompletionEst.
Dec 17, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949123
Lead sponsor
Regina Elena Cancer Institute
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 17, 2025
Primary completion
Oct 26, 2026
Completion
Dec 17, 2026 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion